14 results
10-K
2023 FY
MIRA
Mira Pharmaceuticals Inc
1 Apr 24
Annual report
7:00am
and prepaid expenses, offset by $2.5 million in stock-based compensation expense, $0.7 million in amortization of debt issuance costs, $3.5 million … and line of credit expense, offset by interest income. Accounts payable, accrued and prepaid expenses was primarily composed of research and development
10-Q
2023 Q2
MIRA
Mira Pharmaceuticals Inc
15 Sep 23
Quarterly report
4:45pm
Expenses. During the three months ended June 30, 2023, we incurred $0.3 million in research and development expenses, which were offset by $0.4 million … in research and development expenses, which were offset by $0.4 million in research and development credits. The credits were primarily related to toxicology
424B4
7zi1dvd58hn q8wdq
4 Aug 23
Prospectus supplement with pricing info
1:01pm
424B1
jbubnz shu9tn4vw2s
4 Aug 23
Prospectus with pricing info
12:59pm
S-1
h15r1z 91j8g7ip
29 Jun 23
IPO registration
4:39pm
DRS/A
cr5p82
8 Jun 23
Draft registration statement (amended)
12:00am
DRS/A
z7pflo5hs226dxt25wvt
2 May 23
Draft registration statement (amended)
12:00am
DRS
xbyno 4k4
29 Jun 22
Draft registration statement
12:00am
- Prev
- 1
- Next